CMBA
ITOS

C.M. Bidwell & Associates’s iTeos Therapeutics ITOS Stock Holding History

C.M. Bidwell & Associates’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,929
Closed -$52K – 557
2023
Q2 		$52K Buy
+3,929
New +$56K 0.04% 281

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

C.M. Bidwell & Associates's ITOS Position: Q3 2023 in Review

C.M. Bidwell & Associates sold out of iTeos Therapeutics (ITOS) in Q3 2023, closing a stake of 3,929 shares — an estimated $52K sold.

C.M. Bidwell & Associates first reported a position in ITOS in Q2 2023 and held it in 1 quarter. The position peaked at $52K in Q2 2023. 144 funds tracked by Wall St. Rank hold ITOS as of Q3 2023.

  • C.M. Bidwell & Associates reported no remaining iTeos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 3,929 iTeos Therapeutics shares in Q3 2023, an estimated $52K.
  • C.M. Bidwell & Associates first reported a position in iTeos Therapeutics in Q2 2023 and held it in 1 quarter.
  • C.M. Bidwell & Associates's iTeos Therapeutics position peaked at $52K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2023, filed 13 Nov 2023.